Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesProPhase Labs Inc

ProPhase Labs Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.0051 USD -0.00 ( 10.53%)
Last update at 2026-11-06T16:36:00Z
VOLUME
41032
Market Cap
97.68M

Momentum Score

…

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
4.05
Low
9.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

ProPhase Labs, Inc. provides diagnostic testing services and markets consumer health products focused on infectious disease testing and related OTC items. Long-term growth drivers include sustained demand for infectious-disease diagnostics and expansion of product distribution and testing services, which may support revenue diversification and exposure to recurring testing demand.
Principal investment risks include revenue volatility from changing infectious-disease demand, regulatory and reimbursement uncertainty for diagnostics, competitive pressure from larger manufacturers and limited scale and liquidity typical of small-cap issuers.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
28.71M
Revenue Per Share
1.64
Gross Profit TTM
70.65M
Debt / Equity
0.43
ROE
-45.03%
Net Debt
19.23M
ROCE
33.20%
Diluted EPS TTM
-1.36

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 22.91M 5.30M -2.33M -3.11M -1.47M
Net income 18.46M 6.27M -2.42M -3.01M -1.74M
Selling general administrative 46.41M 22.49M 6.67M 4.48M 4.91M
Selling and marketing expenses - - 1.29M 1.04M 1.11M
Gross profit 70.65M 32.81M 4.61M 2.62M 4.78M
Reconciled depreciation 5.06M 3.56M 0.46M 0.40M 0.38M
Ebit 23.59M 9.80M -3.98M -3.24M -2.02M
Ebitda 28.81M 14.01M -3.46M -2.84M -1.63M
Depreciation and amortization 5.21M 4.21M 0.52M 0.40M 0.38M
Non operating income net other - - 0.06M 0.13M -
Operating income 23.59M 9.80M -3.98M -3.24M -1.63M
Other operating expenses 99.05M 69.24M 18.50M 13.12M 14.76M
Interest expense 0.76M 1.15M 0.29M 0.00M 0.00M
Tax provision 4.45M -0.97M - 0.00M 0.10M
Interest income 0.15M 0.64M 0.06M 0.13M 0.17M
Net interest income -0.61M -0.51M -0.23M 0.13M 0.17M
Extraordinary items - - - -0.04M -0.17M
Income tax expense 4.45M -0.97M 0.09M -0.09M 0.10M
Total revenue 122.65M 79.04M 14.51M 9.88M 13.13M
Total operating expenses 47.06M 23.01M 8.59M 5.85M 6.42M
Cost of revenue 51.99M 46.23M 9.91M 7.26M 8.35M
Total other income expense net -0.69M -4.50M 1.66M 0.13M 0.17M
Discontinued operations - - 0.20M -0.04M -0.17M
Net income from continuing ops 18.46M 6.27M -2.33M -3.11M -1.57M
Net income applicable to common shares - 6.27M -2.12M -3.15M -1.74M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 91.93M 87.65M 89.30M 31.41M 12.27M
Intangible assets 12.33M 8.47M 10.85M 1.23M -
Other current assets 2.15M 2.37M 1.50M 1.24M 0.30M
Total liab 42.54M 24.02M 30.67M 20.85M 1.04M
Total stockholder equity 49.38M 63.63M 58.63M 10.56M 11.23M
Other current liab 6.30M 7.37M 5.80M 2.02M 0.40M
Common stock 0.02M 0.02M 0.02M 0.01M 0.01M
Capital stock 0.02M 0.02M 0.02M 0.01M 0.01M
Retained earnings -5.03M 11.75M 2.64M -3.63M -1.51M
Other liab - 1.28M 0.91M 0.16M 0.11M
Good will 5.23M 5.71M 5.71M 0.90M -
Other assets - 1.28M 1.07M 0.01M -
Cash 2.15M 9.11M 8.41M 6.82M 0.43M
Total current liabilities 20.86M 16.07M 15.52M 6.29M 0.93M
Current deferred revenue 2.38M 2.50M 2.03M 0.17M 0.10M
Net debt 19.23M -2.15M 6.49M 7.91M -0.43M
Short term debt 2.79M 0.30M 0.66M 0.33M -
Short long term debt total 21.38M 6.96M 14.90M 14.72M 0.93M
Other stockholder equity 54.69M 51.10M 56.15M 14.18M 12.72M
Property plant equipment - - 10.35M 8.31M 2.33M
Total current assets 47.59M 60.83M 61.32M 15.89M 9.95M
Net tangible assets - - 42.07M 8.42M 11.23M
Short term investments 3.13M 8.33M 8.86M 1.64M 0.93M
Net receivables 36.31M 37.05M 37.71M 3.15M 6.82M
Long term debt 10.26M 2.40M 10.04M 9.99M -
Inventory 3.84M 3.98M 4.60M 3.04M 1.46M
Accounts payable 9.38M 5.91M 7.03M 3.77M 0.43M
Accumulated other comprehensive income -0.30M 0.76M -0.17M -0.01M -0.00M
Common stock total equity - - - 0.00M 0.01M
Retained earnings total equity - - - -3.63M -1.51M
Treasury stock - - - -47.49M -47.49M
Non currrent assets other -10.34M 1.28M 1.07M 5.07M 2.33M
Non current assets total 44.34M 26.82M 27.98M 15.52M 2.33M
Capital lease obligations 11.12M 4.56M 4.86M 4.73M -
Long term debt total - - - 9.99M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2.08M -19.67M -0.72M 5.77M 12.00M
Change to liabilities 0.48M 5.06M 3.34M -0.26M -0.45M
Total cashflows from investing activities - -19.67M -1.02M 5.54M 11.86M
Net borrowings - -0.04M 10.00M 10.00M 10.00M
Total cash from financing activities -26.02M 35.13M 9.99M -5.82M -11.36M
Change to operating activities - 0.27M -1.44M -0.26M -0.20M
Net income 18.46M 6.27M -2.12M -3.15M -1.74M
Change in cash 0.45M 1.84M 6.38M -1.12M -1.62M
Begin period cash flow 8.66M 6.82M 0.43M 1.55M 3.17M
End period cash flow 9.11M 8.66M 6.82M 0.43M 1.55M
Total cash from operating activities 28.55M -13.62M -2.59M -0.84M -2.12M
Issuance of capital stock 0.00M 40.63M - - -
Depreciation 5.06M 3.56M 0.46M 0.40M 0.38M
Other cashflows from investing activities - -0.70M 1.81M 5.77M 0.00M
Dividends paid 9.35M 4.55M 0.00M 5.82M 11.70M
Change to inventory 0.70M -1.75M -1.47M 0.44M -0.37M
Change to account receivables -4.50M -30.47M -1.04M 0.94M -1.02M
Sale purchase of stock -9.63M -0.92M - - 0.34M
Other cashflows from financing activities -14.52M -19.67M 9.99M 5.54M 0.34M
Change to netincome 9.36M 11.15M -0.32M 0.80M 0.93M
Capital expenditures 3.92M 4.23M 1.69M 0.23M 0.14M
Change receivables - - -1.04M 0.94M -1.02M
Cash flows other operating - - -2.93M -0.01M 0.15M
Cash and cash equivalents changes - - 11.57M -1.12M -1.62M
Change in working capital -4.34M -26.88M -0.61M 1.11M -1.70M
Stock based compensation 3.99M 3.18M 1.46M 0.74M 0.63M
Other non cash items 5.52M -0.31M 0.12M 0.04M 0.17M
Free cash flow 24.63M -17.85M -4.28M -1.07M -2.26M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PRPH
ProPhase Labs Inc		 -0.00
10.53%		 0.01 - 10.09 2.65 2.38 3.02 -9.03
TMO
Thermo Fisher Scientific Inc		 17.82
2.63%		 694.76 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.91
1.73%		 230.25 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.45 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.31
1.23%		 24.85 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

ProPhase Labs Inc

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

711 Stewart Avenue, Garden City, NY, United States, 11530

215 345 0919

https://www.prophaselabs.com

113

Name Title Year Born
Mr. Ted William Karkus Chairman & CEO 1959
Ms. Monica Brady Chief Accounting Officer 1977
Ms. Alice Lioi Exec. VP & Co-COO NA
Mr. Jason Karkus Exec. VP & Co-COO NA
Mr. Sergio Miralles Exec. VP & Chief Information Officer of ProPhase Diagnostics NA
Mr. Billy Joe White Consultant 1961
Mr. Jed A. Latkin Chief Operating Officer & Head of Finance Department 1974
Mr. Robert A. Morse Jr. Controller, Principal Financial Officer & Principal Accounting Officer 1975
Mr. Sergio Miralles Executive VP & Chief Information Officer NA
Mr. Jason Karkus President of Nebula Genomics NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…